Oculis Holding AG (OCS) Total Non-Current Liabilities (2021 - 2026)
Quarterly Total Non-Current Liabilities rose 91.01% to $4.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Mar 2026, up 91.01% year-over-year, with the annual reading at $3.9 million for FY2025, 26.08% up from the prior year.
Oculis Holding AG's Total Non-Current Liabilities history spans 6 years, with the latest figure at $4.4 million for Q1 2026.
- Total Non-Current Liabilities came in at $4.4 million for Q1 2026, up from $3.9 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $127.7 million in Q4 2022 to a low of $938676.2 in Q2 2023.
- The 5-year median for Total Non-Current Liabilities is $2.5 million (2024), against an average of $12.3 million.
- Year-over-year, Total Non-Current Liabilities tumbled 98.64% in 2023 and then skyrocketed 167.65% in 2024.
- Oculis Holding AG's Total Non-Current Liabilities stood at $127.7 million in 2022, then crashed by 98.64% to $1.7 million in 2023, then skyrocketed by 80.18% to $3.1 million in 2024, then grew by 26.08% to $3.9 million in 2025, then grew by 12.97% to $4.4 million in 2026.
- Per Business Quant, the three most recent readings for OCS's Total Non-Current Liabilities are $4.4 million (Q1 2026), $3.9 million (Q4 2025), and $4.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 7.32 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Oculis Holding AG | 24.51 Bn | 24.21 Bn | - | 4.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.45 Mn |
| Dec 31, 2025 | 3.94 Mn |
| Sep 30, 2025 | 4.39 Mn |
| Jun 30, 2025 | 2.39 Mn |
| Mar 31, 2025 | 2.33 Mn |
| Dec 31, 2024 | 3.12 Mn |
| Sep 30, 2024 | 3.07 Mn |
| Jun 30, 2024 | 2.51 Mn |
| Mar 31, 2024 | 1.75 Mn |
| Dec 31, 2023 | 1.73 Mn |
| Sep 30, 2023 | 1.34 Mn |
| Jun 30, 2023 | 938,676.16 |
| Dec 31, 2022 | 127.71 Mn |
| Dec 31, 2021 | 124.65 Mn |